{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:19:49Z","timestamp":1794406789469,"version":"4.9.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s13555-023-01085-w","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T05:02:03Z","timestamp":1704517323000},"page":"83-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9405-0479","authenticated-orcid":false,"given":"Alexa B.","family":"Kimball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Pansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Ciaravino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damon","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Mary","family":"Lewis-Mikhael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita","family":"Tongbram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-6856","authenticated-orcid":false,"given":"Amit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"issue":"1","key":"1085_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat R, Jemec GBE, Matusiak \u0141, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Prim. 2020;6(1):18.","journal-title":"Nat Rev Dis Prim"},{"issue":"8","key":"1085_CR2","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.3390\/cells10082094","volume":"10","author":"E Scala","year":"2021","unstructured":"Scala E, Cacciapuoti S, Garzorz-Stark N, et al. Hidradenitis suppurativa: where we are and where we are going. Cells. 2021;10(8):2094.","journal-title":"Cells"},{"issue":"9","key":"1085_CR3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/jdv.18163","volume":"36","author":"JR Ingram","year":"2022","unstructured":"Ingram JR, Bettoli V, Espy JI, et al. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. J Eur Acad Dermatol Venereol. 2022;36(9):1597\u2013605.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1085_CR4","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1085_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","volume":"82","author":"A Garg","year":"2020","unstructured":"Garg A, Neuren E, Cha D, et al. Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1085_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","volume":"56","author":"P Wolkenstein","year":"2007","unstructured":"Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56(4):621\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"1085_CR7","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.3390\/ijerph18136709","volume":"18","author":"T Montero-Vilchez","year":"2021","unstructured":"Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo JA, et al. The burden of hidradenitis suppurativa signs and symptoms in quality of life: systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18(13):6709.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"1085_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.23736\/S0392-0488.18.06021-2","volume":"154","author":"G Vellaichamy","year":"2019","unstructured":"Vellaichamy G, Braunberger TL, Jones JL, Peacock A, Nahhas AF, Hamzavi IH. Patient-reported outcomes in hidradenitis suppurativa. G Ital Dermatol Venereol. 2019;154(2):137\u201347.","journal-title":"G Ital Dermatol Venereol"},{"key":"1085_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/PROM.S174299","volume":"11","author":"J Mac Mahon","year":"2020","unstructured":"Mac Mahon J, Kirthi S, Byrne N, O\u2019Grady C, Tobin AM. An update on health-related quality of life and patient-reported outcomes in hidradenitis suppurativa. Patient Relat Outcome Meas. 2020;11:21\u20136.","journal-title":"Patient Relat Outcome Meas"},{"issue":"6","key":"1085_CR10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jaad.2017.07.027","volume":"77","author":"IH Hamzavi","year":"2017","unstructured":"Hamzavi IH, Sundaram M, Nicholson C, et al. Uncovering burden disparity: a comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. J Am Acad Dermatol. 2017;77(6):1038\u201346.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1085_CR11","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.3390\/ijerph18116131","volume":"18","author":"PV Chernyshov","year":"2021","unstructured":"Chernyshov PV, Finlay AY, Tomas-Aragones L, et al. Quality of life in hidradenitis suppurativa: an update. Int J Environ Res Public Health. 2021;18(11):6131.","journal-title":"Int J Environ Res Public Health"},{"key":"1085_CR12","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/jamadermatol.2021.2918","volume":"157","author":"P Aarts","year":"2021","unstructured":"Aarts P, Aitken JJ, van Straalen KR. Prevalence of central sensitization in patients with hidradenitis suppurativa. JAMA Dermatol. 2021;157:1209.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1085_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/1346-8138.14722","volume":"46","author":"E Agut-Busquet","year":"2019","unstructured":"Agut-Busquet E, Romani J, Ribera M, Luelmo J. Hidradenitis suppurativa of the nape: description of an atypical phenotype related to severe early-onset disease in men. J Dermatol. 2019;46(2):149\u201353.","journal-title":"J Dermatol"},{"issue":"8","key":"1085_CR14","doi-asserted-by":"publisher","first-page":"adv00107","DOI":"10.2340\/00015555-3464","volume":"100","author":"PL Andersen","year":"2020","unstructured":"Andersen PL, Nielsen RM, Sigsgaard V, Jemec GBE, Riis PT. Body image quality of life in patients with hidradenitis suppurativa compared with other dermatological disorders. Acta Derm Venereol. 2020;100(8):adv00107.","journal-title":"Acta Derm Venereol"},{"key":"1085_CR15","first-page":"137","volume":"157","author":"RD Caposiena Caro","year":"2021","unstructured":"Caposiena Caro RD, Chiricozzi A, Sechi A, et al. Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab. Ital J Dermatol Venerol. 2021;157:137\u201341.","journal-title":"Ital J Dermatol Venerol"},{"issue":"5","key":"1085_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1159\/000513447","volume":"237","author":"M Condamina","year":"2021","unstructured":"Condamina M, Penso L, Tran VT, et al. Baseline characteristics of a National French E-Cohort of hidradenitis suppurativa in ComPaRe and comparison with other large hidradenitis suppurativa cohorts. Dermatology. 2021;237(5):748\u201358.","journal-title":"Dermatology"},{"key":"1085_CR17","first-page":"1","volume":"238","author":"G Fabbrocini","year":"2021","unstructured":"Fabbrocini G, Ruina G, Giovanardi G, et al. Hidradenitis suppurativa in a large cohort of italian patients: evaluation of the burden of disease. Dermatology. 2021;238:1\u201311.","journal-title":"Dermatology"},{"issue":"3","key":"1085_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1684\/ejd.2019.3552","volume":"29","author":"VG Frings","year":"2019","unstructured":"Frings VG, Bauer B, Gloditzsch M, Goebeler M, Presser D. Assessing the psychological burden of patients with hidradenitis suppurativa. Eur J Dermatol. 2019;29(3):294\u2013301.","journal-title":"Eur J Dermatol"},{"issue":"12","key":"1085_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9124046","volume":"9","author":"S Garcovich","year":"2020","unstructured":"Garcovich S, Muratori S, Moltrasio C, et al. Prevalence of neuropathic pain and related characteristics in hidradenitis suppurativa: a cross-sectional study. J Clin Med. 2020;9(12):1\u201311.","journal-title":"J Clin Med"},{"issue":"6","key":"1085_CR20","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/jdv.15353","volume":"33","author":"O Grimstad","year":"2019","unstructured":"Grimstad O, Tzellos T, Dufour DN, et al. Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG). J Eur Acad Dermatol Venereol. 2019;33(6):1164\u201371.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1085_CR21","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.17551","volume":"35","author":"A Hafner","year":"2021","unstructured":"Hafner A, Ghislain PD, Kovacs R, et al. Improvement in hidradenitis suppurativa and quality of life in patients treated with adalimumab: real-world results from the HARMONY study. J Eur Acad Dermatol Venereol. 2021;35:2277.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1085_CR22","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/bjd.14975","volume":"176","author":"IC Janse","year":"2017","unstructured":"Janse IC, Deckers IE, van der Maten AD, et al. Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. Br J Dermatol. 2017;176(4):1042\u20137.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1085_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00403-019-02025-5","volume":"312","author":"AR Jorgensen","year":"2020","unstructured":"Jorgensen AR, Holm JG, Ghazanfar MN, Yao Y, Ring HC, Thomsen SF. Factors affecting quality of life in patients with hidradenitis suppurativa. Arch Dermatol Res. 2020;312(6):427\u201336.","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"1085_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/ijd.15459","volume":"60","author":"AR Jorgensen","year":"2021","unstructured":"Jorgensen AR, Yao Y, Thomsen SF, Ring HC. Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study. Int J Dermatol. 2021;60(7):785\u201391.","journal-title":"Int J Dermatol"},{"issue":"8","key":"1085_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2340\/00015555-2967","volume":"98","author":"K Kaaz","year":"2018","unstructured":"Kaaz K, Szepietowski JC, Matusiak L. Influence of itch and pain on sleep quality in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018;98(8):757\u201361.","journal-title":"Acta Derm Venereol"},{"key":"1085_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ced.14826","volume":"47","author":"N Kashetsky","year":"2021","unstructured":"Kashetsky N, Mukovozov IM, Pereira J, Manion R, Carter S, Alhusayen R. Patient experiences with hidradenitis suppurativa: the hidradenitis patient experience survey. Clin Exp Dermatol. 2021;47:72\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1085_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000475822","volume":"3","author":"AC Katoulis","year":"2017","unstructured":"Katoulis AC, Liakou AI, Rotsiamis N, et al. Descriptive epidemiology of hidradenitis suppurativa in Greece: a study of 152 cases. Skin Appendage Disord. 2017;3(4):197\u2013201.","journal-title":"Skin Appendage Disord"},{"issue":"6","key":"1085_CR28","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/jdv.16132","volume":"34","author":"AB Kimball","year":"2020","unstructured":"Kimball AB, Crowley JJ, Papp K, et al. Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. J Eur Acad Dermatol Venereol. 2020;34(6):1302\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1085_CR29","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamadermatol.2017.3596","volume":"153","author":"JS Kirby","year":"2017","unstructured":"Kirby JS, Butt M, Esmann S, Jemec GBE. Association of resilience with depression and health-related quality of life for patients with hidradenitis suppurativa. JAMA Dermatol. 2017;153(12):1263\u20139.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1085_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/jdv.14511","volume":"32","author":"R Kjaersgaard Andersen","year":"2018","unstructured":"Kjaersgaard Andersen R, Theut Riis P, Jemec GBE. Factors predicting the self-evaluated health of hidradenitis suppurativa patients recruited from an outpatient clinic. J Eur Acad Dermatol Venereol. 2018;32(2):313\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1085_CR31","first-page":"34","volume":"11","author":"PK Krajewski","year":"2021","unstructured":"Krajewski PK, Matusiak L, von Stebut E, et al. Quality-of-life impairment among patients with hidradenitis suppurativa: a cross-sectional study of 1795 patients. Life (Basel). 2021;11(1):34.","journal-title":"Life (Basel)."},{"issue":"1","key":"1085_CR32","first-page":"adv00364","volume":"101","author":"PK Krajewski","year":"2021","unstructured":"Krajewski PK, Matusiak L, von Stebut E, et al. Pain in hidradenitis suppurativa: a cross-sectional study of 1795 patients. Acta Derm Venereol. 2021;101(1):adv00364.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1085_CR33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5070\/D32511046151","volume":"25","author":"M Kremer","year":"2019","unstructured":"Kremer M, Chang TC, Murina A. Presence of arthralgia exacerbates decreased quality of life in hidradenitis suppurativa patients. Dermatol Online J. 2019;25(11):16.","journal-title":"Dermatol Online J"},{"issue":"1","key":"1085_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/bjd.18983","volume":"184","author":"AV Marzano","year":"2021","unstructured":"Marzano AV, Genovese G, Casazza G, et al. Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133\u201340.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1085_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2340\/00015555-2815","volume":"98","author":"L Matusiak","year":"2018","unstructured":"Matusiak L, Szczech J, Kaaz K, Lelonek E, Szepietowski JC. Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018;98(2):191\u20134.","journal-title":"Acta Derm Venereol"},{"key":"1085_CR36","doi-asserted-by":"publisher","DOI":"10.5070\/D3269050156","author":"SA McKenzie","year":"2020","unstructured":"McKenzie SA, Harview CL, Truong AK, et al. Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage. Dermatol Online J. 2020. https:\/\/doi.org\/10.5070\/D3269050156.","journal-title":"Dermatol Online J"},{"issue":"1","key":"1085_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000502139","volume":"236","author":"A Molina-Leyva","year":"2020","unstructured":"Molina-Leyva A, Cuenca-Barrales C. Pruritus and malodour in patients with hidradenitis suppurativa: impact on quality of life and clinical features associated with symptom severity. Dermatology. 2020;236(1):59\u201365.","journal-title":"Dermatology"},{"issue":"1","key":"1085_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14643","volume":"34","author":"V Muralidharan","year":"2021","unstructured":"Muralidharan V, Pathmarajah P, Peterknecht E, et al. Real life data on the biopsychosocial effects of adalimumab in the management of hidradenitis suppurativa: a multicenter cross sectional analysis and consideration of a multisystem monitoring approach to follow up. Dermatol Ther. 2021;34(1):e14643.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1085_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/bjd.18656","volume":"182","author":"RM Nielsen","year":"2020","unstructured":"Nielsen RM, Lindso Andersen P, Sigsgaard V, Theut Riis P, Jemec GB. Pain perception in patients with hidradenitis suppurativa. Br J Dermatol. 2020;182(1):166\u201374.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1085_CR40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1468-3083.2012.04468.x","volume":"27","author":"AJ Onderdijk","year":"2013","unstructured":"Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27(4):473\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1085_CR41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/bjd.17123","volume":"180","author":"A Pavon Blanco","year":"2019","unstructured":"Pavon Blanco A, Turner MA, Petrof G, Weinman J. To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in hidradenitis suppurativa? Br J Dermatol. 2019;180(2):338\u201345.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1085_CR42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ad.2020.08.011","volume":"112","author":"AH Ravn Jorgensen","year":"2021","unstructured":"Ravn Jorgensen AH, Yao Y, Thomsen SF, Christian RH. Self-reported pain alleviating methods in patients with hidradenitis suppurativa. Actas Dermosifiliogr (Engl Ed). 2021;112(2):153\u20138.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"2","key":"1085_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2340\/00015555-2129","volume":"96","author":"PT Riis","year":"2016","unstructured":"Riis PT, Vinding GR, Ring HC, Jemec GB. Disutility in patients with hidradenitis suppurativa: a cross-sectional study using EuroQoL-5D. Acta Derm Venereol. 2016;96(2):222\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1085_CR44","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/bjd.17508","volume":"180","author":"A Rondags","year":"2019","unstructured":"Rondags A, van Straalen KR, van Hasselt JR, et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment. Br J Dermatol. 2019;180(5):1214\u201320.","journal-title":"Br J Dermatol"},{"issue":"16","key":"1085_CR45","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.3390\/jcm10163648","volume":"10","author":"F Sampogna","year":"2021","unstructured":"Sampogna F, Campana I, Fania L, et al. Pain as defining feature of health status and prominent therapeutic target in patients with hidradenitis suppurativa. J Clin Med. 2021;10(16):3648.","journal-title":"J Clin Med"},{"issue":"1","key":"1085_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00403-020-02063-4","volume":"313","author":"F Sampogna","year":"2021","unstructured":"Sampogna F, Fania L, Mastroeni S, Ciccone D, Panebianco A, Abeni D. Age-specific physical and mental health status in Italian patients with hidradenitis suppurativa: a comparison with the general population. Arch Dermatol Res. 2021;313(1):41\u20137.","journal-title":"Arch Dermatol Res"},{"issue":"18","key":"1085_CR47","volume":"100","author":"F Sampogna","year":"2020","unstructured":"Sampogna F, Fania L, Mastroeni S, et al. Correlation between depression, quality of life and clinical severity in patients with hidradenitis suppurativa. Acta Derm Venereol. 2020;100(18):adv00319.","journal-title":"Acta Derm Venereol"},{"key":"1085_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.676241","volume":"8","author":"S Schneider-Burrus","year":"2021","unstructured":"Schneider-Burrus S, Tsaousi A, Barbus S, et al. Features associated with quality of life impairment in hidradenitis suppurativa patients. Front Med (Lausanne). 2021;8: 676241.","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"1085_CR49","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000502296","volume":"5","author":"A Senthilnathan","year":"2019","unstructured":"Senthilnathan A, Kolli SS, Cardwell LA, Richardson IM, Feldman SR, Pichardo RO. Emotional well-being is impaired in hidradenitis suppurativa patients. Skin Appendage Disord. 2019;5(6):366\u20139.","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"1085_CR50","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1590\/abd1806-4841.20197687","volume":"94","author":"IG Tavora","year":"2019","unstructured":"Tavora IG, Bissoli GC, Miot HA, Schmitt JV. Clinical manifestations and quality of life in hidradenitis suppurativa patients: survey of participants from an internet support group. An Bras Dermatol. 2019;94(3):298\u2013303.","journal-title":"An Bras Dermatol"},{"issue":"1","key":"1085_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamadermatol.2020.4494","volume":"157","author":"MT Taylor","year":"2021","unstructured":"Taylor MT, Orenstein LAV, Barbieri JS. Pain severity and management of hidradenitis suppurativa at US emergency department visits. JAMA Dermatol. 2021;157(1):115\u20137.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1085_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","volume":"85","author":"KR van Straalen","year":"2021","unstructured":"van Straalen KR, Tzellos T, Guillem P, et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study. J Am Acad Dermatol. 2021;85(2):369\u201378.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1085_CR53","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40257-017-0280-2","volume":"18","author":"A Vossen","year":"2017","unstructured":"Vossen A, Schoenmakers A, van Straalen KR, Prens EP, van der Zee HH. Assessing pruritus in hidradenitis suppurativa: a cross-sectional study. Am J Clin Dermatol. 2017;18(5):687\u201395.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1085_CR54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ijd.14706","volume":"59","author":"Y Yao","year":"2020","unstructured":"Yao Y, Jorgensen AR, Thomsen SF. Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross-sectional study. Int J Dermatol. 2020;59(3):333\u201340.","journal-title":"Int J Dermatol"},{"issue":"Suppl 2","key":"1085_CR55","first-page":"37","volume":"28","author":"AC Katoulis","year":"2019","unstructured":"Katoulis AC, Lazaridou E, Kontochristopoulos G, et al. A clinico-epidemiological study of hidradenitis suppurativa in Greece: data from three university centers of reference (2016\u20132018). Exp Dermatol. 2019;28(Suppl 2):37.","journal-title":"Exp Dermatol"},{"issue":"Suppl 2","key":"1085_CR56","first-page":"17","volume":"28","author":"C Cuenca-Barrales","year":"2019","unstructured":"Cuenca-Barrales C, RR-VaAM-L. Sexual dysfunction in patients with hidradenitis suppurativa: prevalence and risk factors. Exp Dermatol. 2019;28(Suppl 2):17.","journal-title":"Exp Dermatol"},{"issue":"Suppl 1","key":"1085_CR57","first-page":"37","volume":"30","author":"F Benhadou","year":"2021","unstructured":"Benhadou F, Mintoff D, Guillem P. Do men and women have different clinical characteristics in hidradenitis suppurativa? Exp Dermatol. 2021;30(Suppl 1):37.","journal-title":"Exp Dermatol"},{"issue":"Suppl 1","key":"1085_CR58","first-page":"12","volume":"29","author":"J Romani","year":"2020","unstructured":"Romani J, Garbayo P, Luelmo J. Vulvar hidradenitis suppurativa: an under-diagnosed agony. Clinical and ultrasonographical study of 25 patients. Exp Dermatol. 2020;29(Suppl 1):12.","journal-title":"Exp Dermatol"},{"issue":"4 Suppl 1","key":"1085_CR59","first-page":"AB56","volume":"81","author":"SS Kolli","year":"2019","unstructured":"Kolli SS, Cardwell LA, Richardson I, Feldman SR, Pichardo RO. Emotional well-being is poor in hidradenitis suppurativa patients. J Am Acad Dermatol. 2019;81(4 Suppl 1):AB56.","journal-title":"J Am Acad Dermatol"},{"issue":"4 Suppl 1","key":"1085_CR60","first-page":"AB65","volume":"81","author":"SS Kolli","year":"2019","unstructured":"Kolli SS, Cardwell LA, Richardson I, Feldman SR, Pichardo RO. Fear of negative evaluation correlates with worse quality of life in hidradenitis suppurativa patients. J Am Acad Dermatol. 2019;81(4 Suppl 1):AB65.","journal-title":"J Am Acad Dermatol"},{"issue":"4 Suppl 1","key":"1085_CR61","first-page":"AB81","volume":"81","author":"SS Kolli","year":"2019","unstructured":"Kolli SS, Cardwell LA, Richardson I, Feldman SR, Pichardo RO. Increased stigmatization in hidradenitis suppurativa patients. J Am Acad Dermatol. 2019;81(4 Suppl 1):AB81.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"1085_CR62","first-page":"27","volume":"28","author":"S Schneider-Burrus","year":"2019","unstructured":"Schneider-Burrus S, Gomis-Kleindienst S, Sabat R. The impact of hidradenitis suppurativa on absenteeism, reduced productivity, and work disability. Results from the PIRANHA study. Exp Dermatol. 2019;28(Suppl 2):27.","journal-title":"Exp Dermatol"},{"issue":"5","key":"1085_CR63","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/bjd.18132","volume":"181","author":"A Senthilnathan","year":"2019","unstructured":"Senthilnathan A, Kolli SS, Cardwell LA, Richardson IM, Feldman SR, Pichardo RO. Depression in hidradenitis suppurativa. Br J Dermatol. 2019;181(5):1087\u20138.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"1085_CR64","first-page":"40","volume":"30","author":"PG Vlaeminck-Guillem","year":"2021","unstructured":"Vlaeminck-Guillem PG. Stigmatization feeling in patients with hidradenitis suppurativa. Exp Dermatol. 2021;30(Suppl 1):40.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1085_CR65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000501905","volume":"236","author":"C Cuenca-Barrales","year":"2020","unstructured":"Cuenca-Barrales C, Molina-Leyva A. Risk factors of sexual dysfunction in patients with hidradenitis suppurativa: a cross-sectional study. Dermatology. 2020;236(1):37\u201345.","journal-title":"Dermatology"},{"issue":"23","key":"1085_CR66","doi-asserted-by":"publisher","first-page":"8808","DOI":"10.3390\/ijerph17238808","volume":"17","author":"C Cuenca-Barrales","year":"2020","unstructured":"Cuenca-Barrales C, Molina-Leyva A. Sexuality in patients with hidradenitis suppurativa: beliefs, behaviors and needs. Int J Environ Res Public Health. 2020;17(23):8808.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"1085_CR67","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3390\/jcm8040532","volume":"8","author":"C Cuenca-Barrales","year":"2019","unstructured":"Cuenca-Barrales C, Ruiz-Villaverde R, Molina-Leyva A. Sexual distress in patients with hidradenitis suppurativa: a cross-sectional study. J Clin Med. 2019;8(4):532.","journal-title":"J Clin Med"},{"issue":"5","key":"1085_CR68","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1159\/000513044","volume":"237","author":"C Cuenca-Barrales","year":"2021","unstructured":"Cuenca-Barrales C, Montero-Vilchez T, Salvador-Rodriguez L, Sanchez-Diaz M, Arias-Santiago S, Molina-Leyva A. Implications of hidradenitis suppurativa phenotypes in cardiovascular risk and treatment decisions: a retrospective cohort study. Dermatology. 2021;237(5):727\u201332.","journal-title":"Dermatology"},{"issue":"3","key":"1085_CR69","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.16672","volume":"179","author":"L Thorlacius","year":"2018","unstructured":"Thorlacius L, Ingram JR, Villumsen B, et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179(3):642\u201350.","journal-title":"Br J Dermatol"},{"key":"1085_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7525-1-29","volume":"1","author":"RP Snaith","year":"2003","unstructured":"Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"1085_CR71","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bjd.21821","volume":"187","author":"SB Hasan","year":"2022","unstructured":"Hasan SB, Gendra R, James J, Morris D, Orenstein LAV, Ingram JR. Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa. Br J Dermatol. 2022;187(6):846\u201354.","journal-title":"Br J Dermatol"},{"key":"1085_CR72","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40271-021-00539-7","volume":"15","author":"D Willems","year":"2021","unstructured":"Willems D, Hiligsmann M, van der Zee HH, Sayed CJ, Evers S. Identifying unmet care needs and important treatment attributes in the management of hidradenitis suppurativa: a qualitative interview study. Patient. 2021;15:207\u201318.","journal-title":"Patient"},{"issue":"2","key":"1085_CR73","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40271-022-00614-7","volume":"16","author":"D Willems","year":"2023","unstructured":"Willems D, Hinzpeter EL, Van der Zee HH, et al. Patient preferences in the management of hidradenitis suppurativa: results of a multinational discrete choice experiment in Europe. Patient. 2023;16(2):153\u201364.","journal-title":"Patient"},{"issue":"1","key":"1085_CR74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/bjd.17101","volume":"181","author":"T Tzellos","year":"2019","unstructured":"Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol. 2019;181(1):147\u201354.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1085_CR75","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14737167.2021.1895753","volume":"22","author":"K G\u00e1sp\u00e1r","year":"2022","unstructured":"G\u00e1sp\u00e1r K, Hunor Gergely L, Jenei B, et al. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res. 2022;22(3):399\u2013408.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"1085_CR76","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659\u201364.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1085_CR77","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.18692","volume":"183","author":"JS Kirby","year":"2020","unstructured":"Kirby JS, Thorlacius L, Villumsen B, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. 2020;183(2):340\u20138.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1085_CR78","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/bjd.19344","volume":"184","author":"JS Kirby","year":"2021","unstructured":"Kirby JS, Hereford B, Thorlacius L, et al. Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa. Br J Dermatol. 2021;184(4):681\u20137.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1085_CR79","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/jdv.15425","volume":"33","author":"K Peris","year":"2019","unstructured":"Peris K, Lo Schiavo A, Fabbrocini G, et al. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33(4):766\u201373.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1085_CR80","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/bjd.14475","volume":"175","author":"JR Ingram","year":"2016","unstructured":"Ingram JR, Hadjieconomou S, Piguet V. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol. 2016;175(2):263\u201372.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1085_CR81","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000496923","volume":"235","author":"PV Chernyshov","year":"2019","unstructured":"Chernyshov PV. The evolution of quality of life assessment and use in dermatology. Dermatology. 2019;235(3):167\u201374.","journal-title":"Dermatology"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01085-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T10:03:36Z","timestamp":1730973816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01085-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01085-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexa B. Kimball\u2019s institution received grants from Abbvie, Admirx, Anapyts Bio,\u00a0Aristea, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Moonlake, Novartis, Pfizer, Prometheus, UCB; Sonoma Bio; Chemocentryx; she received consulting fees from Abbvie, Alumis, Bayer,\u00a0Boehringer Ingelheim, Eli Lilly, FIDE, Janssen, Moonlake, Novartis, Pfizer, Priovant, Sonoma Bio, Sanofi, UCB; Target RWE, Ventyx; and serves on the board of directors of Almirall. Joslyn Kirby: Receives a stipend as Editor-in-Chief of the<i> British Journal of Dermatology<\/i> and an authorship honorarium from UpToDate; consultant for Boehringer Ingelheim, ChemoCentryx, Novartis, and UCB Pharma and has served on advisory boards for Insmed, Kymera Therapeutics, and Viela Bio, all in the field of hidradenitis suppurativa (HS); co-copyright holder of HiSQoL, Investigator Global Assessment and Patient Global Assessment instruments for HS; his department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. John R. Ingram: receives a stipend as Editor-in-Chief of the<i> British Journal of Dermatology<\/i> and an authorship honorarium from UpToDate. He is a consultant for Abbvie, Boehringer Ingelheim, ChemoCentryx, Citryll, Novartis, UCB Pharma, and UNION Therapeutics and has served on advisory boards for Insmed, Kymera Therapeutics, and Viela Bio. He is co-copyright holder of HiSQOL, Investigator Global Assessment and Patient Global Assessment instruments for HS. His department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. Tanja Tran: Employee of UCB Pharma. Ingrid Pansar, Valerie Ciaravino, Damon Willems: Employees and shareholders of UCB Pharma. Anne-Mary Lewis-Mikhael, Vanita Tongbram: Employees at Icon plc. Amit Garg: Advisor for AbbVie, Aclaris Therapeutics, Anaptys Bio, Aristea Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, InflaRx, Insmed, Janssen, Novartis, Pfizer, UCB Pharma, Union Therapeutics, and Viela Biosciences, and receives honoraria; research grants from AbbVie, UCB Pharma, and National Psoriasis Foundation; co-copyright holder of the HS IGA and HiSQoL instruments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics approval was not required for this study, as this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}